A Study of a Novel Precision Medicine Approach for Obesity
Phase 4
135
about 3.8 years
18–65
2 sites in FL, MN
What this study is about
Researchers are testing whether a saliva biomarker can predict how well semaglutide works to treat obesity. The trial will last 1378 days and involve approximately 135 participants. Participants will be assigned to receive either a placebo or semaglutide.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Semaglutide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
semaglutide (GLP-1 agonist; stimulates insulin release)
oral (Oral Tablet)
Primary: Change in Total Body Weight at 24 weeks
Secondary: Change in Total Body Weight at 3 months, Change in Total Body Weight at 6 months, Change in Waist Circumference
Endocrinology